Review
Open access
Sep 2026
T‐cell engagers in small cell lung cancer
The current landscape and future directions of DLL3‐targeting TCE in SCLC are discussed, including accumulating real‐world clinical experience, nascent investigation into patient selection and modifiers of response and resistance, and anticipated paradigm shifts as a result of ongoing clinical trials.
Alissa J. Cooper, Jacob M. Sands
· Cancer · 0 citations